Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03603223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab in Treating Participants With Leukoplakia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv16
  2. Primary completion date: Aug 1, 2026 to Aug 1, 2027
    • Study completion date: Aug 1, 2027 to Aug 1, 2028
    v15
  3. Primary completion date: Aug 1, 2025 to Aug 1, 2026
    • Study completion date: Aug 1, 2026 to Aug 1, 2027
    • Site contacts updated at 3 of 3 sites
    v14
  4. Primary completion date: Dec 1, 2024 to Aug 1, 2025
    • Study completion date: Dec 1, 2025 to Aug 1, 2026
    • Site contacts updated at 3 of 3 sites
    v13
  5. Primary completion date: Jun 1, 2024 to Dec 1, 2024
    • Study completion date: Jun 1, 2025 to Dec 1, 2025
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date: Jun 1, 2023 to Jun 1, 2024
    • Study completion date: Jun 1, 2024 to Jun 1, 2025
    v11
  2. Re-verified, no change to tracked fieldsv10
  3. Primary completion date: Jun 1, 2022 to Jun 1, 2023
    • Study completion date: Jun 1, 2023 to Jun 1, 2024
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Primary completion date: Jun 1, 2021 to Jun 1, 2022
    • Study completion date: Jun 1, 2022 to Jun 1, 2023
    v7
  6. Collaborators: 2 to 1v6
  7. Re-verified, no change to tracked fieldsv5
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2019 to May 3, 2019
    • Site details revised at 3 of 3 sites
    v4
  9. Primary completion date: Dec 1, 2020 to Jun 1, 2021
    • Start date: Dec 1, 2018 to Jun 1, 2019
    • Study completion date: Dec 1, 2021 to Jun 1, 2022
    v3
  10. Start date: Aug 1, 2018 to Dec 1, 2018
    • Primary completion date: Aug 1, 2020 to Dec 1, 2020
    • Study completion date: Aug 1, 2021 to Dec 1, 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Trial Details
NCT Number NCT03603223
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia
Related terms Leukoplakia
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov